Altimmune's Fatty Liver Candidate Faces Differentiation Doubts

Altimmune, Inc. reported mixed topline results from its pemvidutide Phase 2b trial for MASH, showing statistically significant MASH resolution at 24 weeks (59.1% and 52.1% for active doses vs. 19.1% for placebo) but no statistically significant fibrosis improvement, leading to a slight stock decline. This outcome has generated divergent analyst views: HC Wainwright maintained a Buy rating and $12 price target, anticipating positive 48-week fibrosis data and best-in-class potential, while William Blair reiterated Market Perform, citing "underwhelming" 24-week fibrosis results and competitive market concerns.

Analysis

Altimmune, Inc. has reported a mixed set of topline results from its IMPACT Phase 2b trial for pemvidutide in MASH, creating a clear divergence in analyst sentiment. The trial demonstrated strong, statistically significant MASH resolution without worsening of fibrosis at 24 weeks, with 59.1% and 52.1% of participants in the 1.2 mg and 1.8 mg dose groups achieving this endpoint, respectively, compared to just 19.1% for placebo (p<0.0001). However, the study failed to meet its other primary endpoint, showing no statistically significant improvement in fibrosis (31.8% and 34.5% for the active doses versus 25.9% for placebo). This has led HC Wainwright to reiterate a Buy rating and a $12 price target, viewing the stock's decline as overdone and anticipating a positive fibrosis readout at the 48-week mark. Conversely, William Blair maintained a Market Perform rating, labeling the results "underwhelming" due to the missed fibrosis endpoint and expressing skepticism about the 48-week data, which will not include a liver biopsy. The market's reaction, a modest 1.80% decline to $3.545, reflects this ambiguity, weighing the strong MASH resolution against the critical failure on fibrosis and concerns about pemvidutide's differentiation in a competitive field.

Key Decisions for Investors

• Investors with a higher risk appetite may view the current stock price as an opportunity, aligning with HC Wainwright's thesis that the market is overlooking the strong MASH resolution data and the potential for positive 48-week results.
• More cautious investors should heed William Blair's concerns, focusing on the failure to achieve statistically significant fibrosis improvement at 24 weeks, a key hurdle in the competitive MASH therapeutic landscape.
• The primary forward-looking catalyst is the 48-week data; therefore, investors should monitor for any company guidance on this readout, as its outcome will be critical in resolving the current analyst debate and determining the drug's future viability.